Recognition and rewards

The company is seriously committed to access to inclusive healthcare, reducing the treatment gap for underprivileged people, capacity building and continuous education and to performing business ethically and responsibly.

UCB’s efforts were recognized in 2017 by the London Stock Exchange’s FTSE4Good Index, ECPI and Corporate Knights.

The EURORDIS Company Award has been awarded to UCB in recognition of our leadership in championing patient engagement via an Innovative Medicines Initiative (IMI) project called PARADIGM.  In addition, UCB Iberia has won the ‘Best Ideas’ Award for their ‘Neurology Educational Center Program’ (known as ‘CEN’), an initiative to help patients with Parkinsons disease by improving their quality of life.

Finally, UCB colleagues in China received the ‘Best Company Award 2017’ at the Best of BenCham Award Ceremony, in ‘recognition of UCB’s Patient Value Strategy and impact on society’.